Home Cart Sign in  
Chemical Structure| 5928-25-6 Chemical Structure| 5928-25-6

Structure of Decursin
CAS No.: 5928-25-6

Chemical Structure| 5928-25-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Decursin ((+)-Decursin) is an effective anticancer agent and a cytotoxic and potent activator of protein kinase C (PKC). Decursin induces apoptosis and cell cycle arrest in the G1 phase. Decursin reduces the expression of CDK2, CDK4, CDK6, and cyclin D1 proteins at 48 hours. Decursin inhibits cell proliferation and migration and exhibits antitumor, anti-inflammatory, and analgesic activities.

Synonyms: (+)-Decursin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Decursin

CAS No. :5928-25-6
Formula : C19H20O5
M.W : 328.36
SMILES Code : CC(C)=CC(O[C@@H]1C(C)(C)OC2=C(C=C(C=CC(O3)=O)C3=C2)C1)=O
Synonyms :
(+)-Decursin
MDL No. :MFCD00272154

Safety of Decursin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Decursin

epigenetics
RTK
GPCR

Isoform Comparison

Biological Activity

Description
Decursin, identified as (+)-Decursin, serves as a potent anti-tumor agent with additional cytotoxic properties and the ability to activate protein kinase C significantly. It triggers apoptosis and causes cell cycle arrest in the G1 phase while reducing the expression of CDK2, CDK4, CDK6, and cyclin D1 proteins over 48 hours. Beyond its anti-tumor capacity, Decursin also displays anti-inflammatory and analgesic effects, inhibiting cell proliferation and migration[1].[2].[3].[4].

In Vitro:

Cell Line
Concentration Treated Time Description References
BEAS-2B 60 μM 1 h To evaluate the effect of Decursin on ROS generation in normal cells, results showed that Decursin did not significantly induce ROS generation in normal cells Br J Pharmacol. 2016 Mar;173(6):1033-44
Calu-1 150 μM 24 h To evaluate the effect of Decursin on cell viability, results showed that Decursin significantly reduced the viability of NSCLC cells Br J Pharmacol. 2016 Mar;173(6):1033-44
H1299 150 μM 24 h To evaluate the effect of Decursin on cell viability, results showed that Decursin significantly reduced the viability of NSCLC cells Br J Pharmacol. 2016 Mar;173(6):1033-44
H596 150 μM 24 h To evaluate the effect of Decursin on cell viability, results showed that Decursin significantly reduced the viability of NSCLC cells Br J Pharmacol. 2016 Mar;173(6):1033-44
A549 150 μM 24 h To evaluate the effect of Decursin on cell viability, results showed that Decursin significantly reduced the viability of NSCLC cells Br J Pharmacol. 2016 Mar;173(6):1033-44
HT22 cells 25 and 50 µM 6 h Evaluate the effect of Decursin on HO-1 expression in HT22 cells, results showed Decursin significantly increased HO-1 expression levels. Antioxidants (Basel). 2023 Aug 21;12(8):1651
HT22 cells 25 and 50 µM 8 h Evaluate the effect of Decursin on glutamate-induced ROS accumulation in HT22 cells, results showed Decursin significantly reduced ROS accumulation. Antioxidants (Basel). 2023 Aug 21;12(8):1651
HT22 cells 25 µM 12 h Evaluate the protective effect of Decursin on glutamate-induced chromatin condensation in HT22 cells, results showed Decursin significantly reduced chromatin condensation. Antioxidants (Basel). 2023 Aug 21;12(8):1651
HT22 cells 12.5 and 25 µM 24 h Evaluate the protective effect of Decursin on glutamate-induced HT22 cell death, results showed Decursin significantly improved cell viability. Antioxidants (Basel). 2023 Aug 21;12(8):1651
F11 cells 2 μM 12 h Decursin significantly increased the number and length of neurites in F11 cells, promoting neuronal regeneration. Cells. 2021 Mar 4;10(3):547
F11 cells 0.5 and 1 μM 30 seconds Decursin significantly inhibited the rapid elevation of intracellular Ca2+ levels induced by capsaicin in a concentration-dependent manner. Cells. 2021 Mar 4;10(3):547
HCT-8 colorectal cancer cells 3.125, 6.25, 12.5, 25, 50, 100, 200 µM 24, 48, 72 h To evaluate the effect of Decursin on the growth of HCT-8 cells, results showed that Decursin inhibited cell viability in a dose- and time-dependent manner. Int J Mol Sci. 2024 Sep 14;25(18):9939
HCT-116 colorectal cancer cells 3.125, 6.25, 12.5, 25, 50, 100, 200 µM 24, 48, 72 h To evaluate the effect of Decursin on the growth of HCT-116 cells, results showed that Decursin inhibited cell viability in a dose- and time-dependent manner. Int J Mol Sci. 2024 Sep 14;25(18):9939
Peripheral blood lymphocytes (PBL) 80 μM 24 h To evaluate the cytotoxic effect of Decursin on PBL, results showed no cytotoxicity at concentrations up to 80 μM. Cancer Lett. 2010 Dec 8;298(2):212-21
U937 cells 20, 80 μM 24 h To evaluate the cytotoxic effect of Decursin on U937 cells, results showed cytotoxicity starting at 20 μM, becoming prominent at 80 μM. Cancer Lett. 2010 Dec 8;298(2):212-21
HL-60 cells 80 μM 24 h To evaluate the cytotoxic effect of Decursin on HL-60 cells, results showed an apoptotic effect at 80 μM. Cancer Lett. 2010 Dec 8;298(2):212-21
KBM-5 cells 10, 20, 40, 80 μM 24 h To evaluate the cytotoxic effect of Decursin on KBM-5 cells, results showed that Decursin started to be cytotoxic at 10 μM and exhibited dose-dependent cytotoxicity. Cancer Lett. 2010 Dec 8;298(2):212-21

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Paclitaxel-induced neuropathic pain model Intrathecal injection 50 mg/kg Every 2 days, 3 times in total, lasting 6 days Decursin significantly alleviated mechanical allodynia in paclitaxel-induced neuropathic pain mice, and the effect was more prolonged with increased injection frequency. Cells. 2021 Mar 4;10(3):547
BALB/c nude mice HCT-116 and HCT-8 colorectal cancer cell subcutaneous xenograft model Intraperitoneal injection 10 mg/kg Twice weekly for 14 days To evaluate the effect of Decursin on the growth of HCT-116 and HCT-8 xenografts, results showed that Decursin significantly suppressed tumor growth without causing host toxicity. Int J Mol Sci. 2024 Sep 14;25(18):9939
Nude mice Subcutaneous xenograft model Intraperitoneal injection 10 mg/kg On days 1, 3, 5, and 7 To validate the anti-tumor efficacy of Decursin in vivo. The results showed that Decursin significantly inhibited tumor growth and no significant systemic toxicity was observed. Int J Mol Sci. 2025 Jun 4;26(11):5391

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.05mL

0.61mL

0.30mL

15.23mL

3.05mL

1.52mL

30.45mL

6.09mL

3.05mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories